Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038161072> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2038161072 abstract "Background: Inflammatory breast cancer (IBC) is a highly lethal form of breast cancer which is characterized by skin redness, irritation, swelling, pain, as well as extensive lymph nodes (LN) and hematogenous metastasis. Animal models of IBC are highly desirable for studying its pathology and for designing effective therapies. In this study, we established two new luciferase-and fluorescently-labeled IBC models and tested the efficacy of the novel drug combination nab-paclitaxel and bevacizumab. Methods: Inflammatory SUM149 breast cancer cells were stably transfected with Red Fluorescent Protein (RFP) and Renilla luciferase to establish SUM149-RR, or infected with lentivirus encoding Green Fluorescent Protein (GFP) and Firefly luciferase to establish SUM149- GL. The new cell lines were characterized both in vitro and in vivo. Immunodeficient mice bearing SUM149-RR tumors of 150mm 3 in size were treated with saline (control), bevacizumab (4 mg/kg, i.p., twice a week, for 10 weeks), nab-paclitaxel (10 mg/kg, i.v., qdx5), or the combination. Metastasis was analyzed by measuring luciferase activity in the lymph nodes (LN) and lungs. Results: Luciferase measurements and in vivo imaging showed that both SUM149-RR and-GL clones were highly metastatic to LN, lungs, liver, brain, and spleen. SUM149-RR tumors in control mice displayed ulcerations, edema and redness similar to the clinical disease, while tumors in mice treated with bevacizumab or combination therapy showed no signs of inflammation. Bevacizumab alone decreased tumor growth at later but not early stages of tumor growth, whereas nab-paclitaxel alone inhibited tumor growth by 73%. Combination therapy increased inhibition to 96%, and resulted in 22% (2/9) complete responses. Histologically, tumors from bevacizumab treated groups were more morphologically intact with reduced vascular abnormalities than tumors from control or nab-paclitaxel treated mice. LN and lung metastasis was significantly reduced in all treated groups as compared with control. Conclusions: The SUM149-RR and SUM149-GL lines are new double-tagged models of human IBC that allow organ visualization and accurate quantification of metastasis. These models can be used to study the biology and treatment of IBC. Combination of nab -paclitaxel with bevacizumab was highly effective against SUM149-RR, suggesting the potential usefulness of this regimen for treatment of IBC patients. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-03-09." @default.
- W2038161072 created "2016-06-24" @default.
- W2038161072 creator A5012599222 @default.
- W2038161072 creator A5071716684 @default.
- W2038161072 creator A5080772475 @default.
- W2038161072 creator A5085492782 @default.
- W2038161072 creator A5091825398 @default.
- W2038161072 date "2010-12-15" @default.
- W2038161072 modified "2023-09-22" @default.
- W2038161072 title "Abstract P1-03-09: Combination ofnab-Paclitaxel and Bevacizumab Inhibited Tumor Growth and Metastasis of New Inflammatory Breast Cancer Models" @default.
- W2038161072 doi "https://doi.org/10.1158/0008-5472.sabcs10-p1-03-09" @default.
- W2038161072 hasPublicationYear "2010" @default.
- W2038161072 type Work @default.
- W2038161072 sameAs 2038161072 @default.
- W2038161072 citedByCount "0" @default.
- W2038161072 crossrefType "proceedings-article" @default.
- W2038161072 hasAuthorship W2038161072A5012599222 @default.
- W2038161072 hasAuthorship W2038161072A5071716684 @default.
- W2038161072 hasAuthorship W2038161072A5080772475 @default.
- W2038161072 hasAuthorship W2038161072A5085492782 @default.
- W2038161072 hasAuthorship W2038161072A5091825398 @default.
- W2038161072 hasConcept C111335760 @default.
- W2038161072 hasConcept C121608353 @default.
- W2038161072 hasConcept C126322002 @default.
- W2038161072 hasConcept C142724271 @default.
- W2038161072 hasConcept C150903083 @default.
- W2038161072 hasConcept C207001950 @default.
- W2038161072 hasConcept C2775930923 @default.
- W2038161072 hasConcept C2776694085 @default.
- W2038161072 hasConcept C2777292972 @default.
- W2038161072 hasConcept C2777802072 @default.
- W2038161072 hasConcept C2779013556 @default.
- W2038161072 hasConcept C2780839634 @default.
- W2038161072 hasConcept C502942594 @default.
- W2038161072 hasConcept C530470458 @default.
- W2038161072 hasConcept C54009773 @default.
- W2038161072 hasConcept C54355233 @default.
- W2038161072 hasConcept C71924100 @default.
- W2038161072 hasConcept C81885089 @default.
- W2038161072 hasConcept C86803240 @default.
- W2038161072 hasConceptScore W2038161072C111335760 @default.
- W2038161072 hasConceptScore W2038161072C121608353 @default.
- W2038161072 hasConceptScore W2038161072C126322002 @default.
- W2038161072 hasConceptScore W2038161072C142724271 @default.
- W2038161072 hasConceptScore W2038161072C150903083 @default.
- W2038161072 hasConceptScore W2038161072C207001950 @default.
- W2038161072 hasConceptScore W2038161072C2775930923 @default.
- W2038161072 hasConceptScore W2038161072C2776694085 @default.
- W2038161072 hasConceptScore W2038161072C2777292972 @default.
- W2038161072 hasConceptScore W2038161072C2777802072 @default.
- W2038161072 hasConceptScore W2038161072C2779013556 @default.
- W2038161072 hasConceptScore W2038161072C2780839634 @default.
- W2038161072 hasConceptScore W2038161072C502942594 @default.
- W2038161072 hasConceptScore W2038161072C530470458 @default.
- W2038161072 hasConceptScore W2038161072C54009773 @default.
- W2038161072 hasConceptScore W2038161072C54355233 @default.
- W2038161072 hasConceptScore W2038161072C71924100 @default.
- W2038161072 hasConceptScore W2038161072C81885089 @default.
- W2038161072 hasConceptScore W2038161072C86803240 @default.
- W2038161072 hasLocation W20381610721 @default.
- W2038161072 hasOpenAccess W2038161072 @default.
- W2038161072 hasPrimaryLocation W20381610721 @default.
- W2038161072 hasRelatedWork W1520571564 @default.
- W2038161072 hasRelatedWork W1768539124 @default.
- W2038161072 hasRelatedWork W1991724348 @default.
- W2038161072 hasRelatedWork W2067746840 @default.
- W2038161072 hasRelatedWork W2083652600 @default.
- W2038161072 hasRelatedWork W2116488335 @default.
- W2038161072 hasRelatedWork W2148861440 @default.
- W2038161072 hasRelatedWork W2265208154 @default.
- W2038161072 hasRelatedWork W2309122708 @default.
- W2038161072 hasRelatedWork W2323447216 @default.
- W2038161072 hasRelatedWork W2329078418 @default.
- W2038161072 hasRelatedWork W2369255009 @default.
- W2038161072 hasRelatedWork W2376727540 @default.
- W2038161072 hasRelatedWork W2549961143 @default.
- W2038161072 hasRelatedWork W2566930261 @default.
- W2038161072 hasRelatedWork W2636701103 @default.
- W2038161072 hasRelatedWork W2742026430 @default.
- W2038161072 hasRelatedWork W2794016029 @default.
- W2038161072 hasRelatedWork W3159761971 @default.
- W2038161072 hasRelatedWork W2468703096 @default.
- W2038161072 isParatext "false" @default.
- W2038161072 isRetracted "false" @default.
- W2038161072 magId "2038161072" @default.
- W2038161072 workType "article" @default.